

# Avotres Inc. Founder and CSO, Dr. Hong Jiang Presented at the 7th Treg-Directed Therapies Summit

BOSTON, MA, UNITED STATES, March 26, 2025 /EINPresswire.com/ -- [Avotres](#) proudly announces the successful presentation, titled as "Analyzing the Q/E CD8+ Treg Pathway to Unlock Effective Clinical Applications: Q/E CD8+Treg Pathway Directed Therapy for Type 1 Diabetes", by its Founder and Chief Scientific Officer, Dr. Hong Jiang, at the [7th Treg-Directed Therapies Summit](#), held from March 25-27, 2025, in Boston, MA, took place on March 25 at 9:30 AM EST during the Treg Biology Focus Day.

Dr. Jiang's presentation provided groundbreaking insights into the Q/E CD8+ Treg pathway, a unique mechanism critical to immune regulation and therapeutic advancements.

She detailed:

- The underlying biology of the Q/E CD8+ Treg pathway and its role in "Peripheral self-nonsel self discrimination" process during adaptive immunity, which is to complete the entire "self-nonsel self discrimination" process for achieving and maintaining self-tolerance status, after the central thymic negative selection has been successfully accomplished.
- Key findings from preclinical in-vitro and in vivo studies in two autoimmune diseases animal models NOD and EAE, and 8 human ex vivo studies in auto-immune diseases, including Type 1 Diabetes, Multiple Sclerosis, Psoriasis, Rheumatoid Arthritis, Lupus, Vitiligo, Dermatomyositis and Pemphigus.
- Safety and efficacy results from recently completed Phase I/II clinical trials in Type 1 Diabetes.
- Innovative platforms for drug manufacturing and precision detective assay system development.

Dr. Jiang's insights were met with enthusiasm from attendees, including top researchers,



**7th Annual Treg-Directed Therapies Summit**  
Driving Treg Cell Therapies & Modulators from Concept to Clinic

**EXPERT SPEAKER**

**Hong Jiang**  
Founder & Chief Scientific Officer  
Avotres

Dr. Hong Jiang presented at 7th Treg-Directed Therapies Summit.

industry leaders, and biotech innovators. Her findings highlighted the potential of the Q/E CD8+ Treg pathway to transform immune tolerance therapies, offering new hope for patients with autoimmune diseases.

“The response to our research has been overwhelmingly positive, reinforcing the significance of the Q/E CD8+ Treg pathway in advancing immune therapies,” said Dr. Jiang. “I was honored to engage in meaningful discussions with colleagues and look forward to furthering collaborations that will drive this research forward.”

The 7th Treg-Directed Therapies Summit once again proved to be a premier gathering for those at the forefront of regulatory T cell research. The event facilitated the exchange of cutting-edge ideas and fostered collaborations aimed at accelerating the development of next-generation immune therapies.

For more information about Dr. Jiang’s presentation or to discuss potential collaborations with Avotres, please contact Tuochuan Dong at [tuochuan.dong@avotres.com](mailto:tuochuan.dong@avotres.com).

#### About Avotres

Avotres is a pioneering biotechnology company dedicated to developing novel immune-regulating therapies targeting autoimmune diseases and other immune disorders. By leveraging the power of regulatory T cells, Avotres aims to revolutionize treatment paradigms and improve patient outcomes.

Tuochuan Dong

Avotres Inc.

[tuochuan.dong@avotres.com](mailto:tuochuan.dong@avotres.com)

Visit us on social media:

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/797160468>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.